Status:
COMPLETED
Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2
Lead Sponsor:
PowderMed
Conditions:
HSV-2
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the abi...
Detailed Description
Herpes simplex virus type 2 (HSV-2) infection is a serious public health problem, with up to 20% of the US population infected. Following primary infection, HSV-2 establishes a latent infection that c...
Eligibility Criteria
Inclusion
- Otherwise healthy subjects with recurrent genital herpes due to HSV-2 infection
Exclusion
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00274300
Start Date
August 1 2004
End Date
July 1 2005
Last Update
January 29 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Westover Heights Clinic
Portland, Oregon, United States, 97210
2
Center for Clinical Studies
Houston, Texas, United States, 77058